2 terminated. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Phase 2 | 2 | Terminated 2 |
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 1/2 Study to Evaluate Safety, PK and Efficacy of the MYC-Inhibitor OMO-103 in Solid Tumours OMO-103 - Advanced Solid Tumors, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Peptomyc S.L. | 22 | 2021-04-28 | 2024-04-25 |
| Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors CB-839, Talazoparib - Solid Tumor, Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 33 | 2019-05-20 | 2022-02-17 |
Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms (2) · Neoplasms by Site (2) · Adenocarcinoma (1) · Breast Diseases (1) · Breast Neoplasms (1) · Carcinoma (1) · Colonic Diseases (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1)
CB-839 (1) · talazoparib (1)
Calithera Biosciences, Inc (1) · Peptomyc S.L. (1)
Spain (1) · United States (1)
Elena Garralda, MD, PhD (1) · Sam Whiting, MD, PhD (1)